Overview

• The Map and Alma‑Care initiatives, presented with input from more than 140 specialists, produced over 40 recommendations with 14 flagged as essential to prepare services for disease‑modifying treatment.
• Specialists cite limited consultation time, insufficient training and scarce diagnostic tools as the leading barriers to detecting the disease in its initial stages.
• Referral from primary care usually takes under three months, yet the first specialist appointment often exceeds six months, creating roughly a nine‑month pathway to diagnosis.
• Lecanemab and donanemab hold EU approval but are not yet in Spain’s public service portfolio, prompting calls to scale biomarker testing, MRI access, day‑hospital capacity and multidisciplinary teams.
• Neurology society data indicate more than half of mild cases remain undiagnosed with an average delay beyond two years, while experts stress early detection to qualify patients for therapies reported to slow decline and extend life expectancy.